Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

100%

6 trials in Phase 3/4

Results Transparency

100%

4 of 4 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 4

6(100.0%)

6Total

Phase 4(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05058976Phase 4Active Not Recruiting

Romosozumab Use to Build Skeletal Integrity

Role: lead

NCT06118905Phase 4Recruiting

Preserving Geriatric Muscle With an Osteoporosis Medication

Role: lead

NCT02753283Phase 4Completed

Preventing Osteoporosis Using Denosumab

Role: lead

NCT02589600Phase 4Completed

Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)

Role: lead

NCT01705587Phase 4Completed

Fracture (FX) Improvement With Teriparatide: FiX-IT Study

Role: lead

NCT00485953Phase 4Completed

Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy

Role: lead

All 6 trials loaded